Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.1,2
Full indication for Cosentyx can be found here
Help your newly initiated Cosentyx patients keep track of their treatment with a digital dosing schedule. As a healthcare professional, you should download the relevant documents and fill in the patient’s planned injection dates.
Share the completed file with your patients and they can simply tick the circles after they administer their Cosentyx dose, as shown in the example below:
Please note that this resource is designed for optimal use on desktop or tablet. Functionality may be restricted on some devices, including mobile.
Do not share links to this website or screenshots with patients as this website is intended for healthcare professionals only.
Q2W (every 2 weeks) dosing with Cosentyx is for adult patients with a body weight of ≥90 kg, with psoriatic arthritis and concomitant plaque psoriasis.1,2
Please note that this resource is designed for optimal use on desktop or tablet. Functionality may be restricted on some devices, including mobile.
Do not share links to this website or screenshots with patients as this website is intended for healthcare professionals only.
Please note that this resource is designed for optimal use on desktop or tablet. Functionality may be restricted on some devices, including mobile.
Do not share links to this website or screenshots with patients as this website is intended for healthcare professionals only.
For more information on Cosentyx dosing, please see dosing and product information.
Therapeutic Indications1,2
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.1,2
AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; HS, hidradenitis suppurativa; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, plaque psoriasis; Q2W, every 2 weeks.
References
- Cosentyx® (secukinumab) GB Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/3669/smpc [Accessed January 2024].
- Cosentyx® (secukinumab) NI Summary of Product Characteristics. Available at: https://www.emcmedicines.com/en-gb/northernireland/medicine?id=627fbcd7-... [Accessed January 2024].